160 related articles for article (PubMed ID: 35414476)
21. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
23. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma.
Yamaoka K; Irie K; Hiramoto N; Hirabatake M; Ikesue H; Hashida T; Shimizu T; Ishikawa T; Muroi N
Invest New Drugs; 2023 Oct; 41(5):761-767. PubMed ID: 37721661
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
[TBL] [Abstract][Full Text] [Related]
25. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Blair HA
Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of subcutaneous daratumumab injections in the ambulatory care setting.
Tam AH; Jung Y; Young R; Huang CY; Wolf J; Shah N; Wong SW; Martin TG; Lo M
J Oncol Pharm Pract; 2022 Dec; 28(8):1819-1825. PubMed ID: 34647506
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
Arnall JR; Maples KT; Harvey RD; Moore DC
Ann Pharmacother; 2022 Aug; 56(8):927-940. PubMed ID: 34963325
[TBL] [Abstract][Full Text] [Related]
28. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
30. Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review.
Troisi S; Giudice V; Troisi M; Morini D; Crudele A; Cuffa B; Selleri C; Serio B
Acta Haematol; 2023; 146(5):424-430. PubMed ID: 37331348
[TBL] [Abstract][Full Text] [Related]
31. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
Moore DC; Arnall JR; Thompson DL; Martin AL; Robinson J; Ndiaye A; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e777-e781. PubMed ID: 32660902
[TBL] [Abstract][Full Text] [Related]
33. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
34. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
Aykaş F; Karakuş V; Sevindik ÖG
J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462
[No Abstract] [Full Text] [Related]
36. Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Slavcev M; Spinelli A; Absalon E; Masterson T; Heuck C; Lam A; De Cock E
Clinicoecon Outcomes Res; 2021; 13():465-473. PubMed ID: 34135605
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with Multiple Myeloma.
Li X; Dosne AG; Pérez Ruixo C; Perez Ruixo JJ
Clin Pharmacokinet; 2023 May; 62(5):761-777. PubMed ID: 37022569
[TBL] [Abstract][Full Text] [Related]
38. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study.
Rifkin R; Singer D; Aguilar KM; Baidoo B; Maiese EM
Clin Ther; 2019 May; 41(5):866-881.e7. PubMed ID: 31030993
[TBL] [Abstract][Full Text] [Related]
39. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
Paul B; Hamadeh I; Atrash S; Bhutani M; Voorhees P; Usmani SZ
Expert Opin Biol Ther; 2020 Nov; 20(11):1253-1259. PubMed ID: 32750265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]